Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 549,400 shares, a growth of 36.8% from the November 15th total of 401,700 shares. Currently, 2.5% of the shares of the stock are short sold. Based on an average daily volume of 72,700 shares, the days-to-cover ratio is presently 7.6 days.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC acquired a new stake in shares of Gyre Therapeutics in the 3rd quarter worth approximately $47,000. Barclays PLC boosted its position in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. State Street Corp boosted its position in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Rhumbline Advisers acquired a new stake in Gyre Therapeutics in the second quarter valued at $123,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Gyre Therapeutics in the second quarter valued at $166,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Stock Down 1.4 %

Shares of NASDAQ GYRE traded down $0.14 during midday trading on Friday, hitting $9.64. The company had a trading volume of 138,657 shares, compared to its average volume of 73,604. The business has a 50-day simple moving average of $13.14 and a two-hundred day simple moving average of $12.59. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $30.40.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.